The expression of Bcl-2 family proteins differs between nonsmall cell lung carcinoma subtypes

被引:32
作者
Berrieman, HK
Smith, L
O'Kane, SL
Campbell, A
Lind, MJ
Cawkwell, L
机构
[1] Univ Hull, Hull York Med Sch, Postgrad Med Inst, Kingston Upon Hull HU6 7RX, N Humberside, England
[2] Hull Royal Infirm, Dept Histopathol, Kingston Upon Hull HU3 2JZ, N Humberside, England
关键词
lung carcinoma; apoptosis; Bcl-2; family; immunohistochemistry;
D O I
10.1002/cncr.20907
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
BACKGROUND. Proteins of the Bcl-2 family play a key role in the control of apoptosis and carry out both proapoptotic and antiapoptotic functions. However, with the exception of Bcl-2 itself, little is known about the expression of these potentially critical proteins in nonsmall cell lung carcinoma. METHODS. Immunohistochemistry was used to study the expression of Bcl-2 and 6 other Bcl-2 family proteins in a pilot series of 41 archival nonsmall cell lung carcinoma specimens (19 adenocarcinomas and 22 squamous cell carcinomas). RESULTS. Overexpression of the apoptosis inhibitors Bcl-2 and Bcl-X-L was observed in 10 of 41 samples (24%) and in 11 of 41 samples (27%), respectively. Loss of expression of proapoptotic proteins was observed as follows: Bak, 24 of 41 samples (59%); Bad, 21 of 41 samples (51%); Bid, 20 of 41 samples (49%); Bax, 14 of 41 samples (34%); and Bim/Bod, 2 of 41 samples (5%). Statistically significant differences in expression between adenocarcinoma samples and squamous cell carcinoma samples were observed for Bcl-X-L (overexpression in 11 of 19 adenocarcinomas [58%] vs. 0 of 22 squamous cell carcinomas [0%]; P < 0.001) and for Bad (loss of expression in 5 of 19 adenocarcinomas [26%] vs. 16 of 22 squamous cell carcinomas [73%]; P = 0.004). CONCLUSIONS. Although this was only a pilot study, the results revealed significant differences in the expression of apoptosis-related proteins both between individual samples of nonsmall cell lung carcinoma and between the two main histologic subtypes. Such differences may play a role in the development of lung tumors; and, if it is found that these differences are of clinical importance, then it may be required to regard nonsmall cell lung carcinoma subtypes as separate entities rather than as one disease. (c) 2005 American Cancer Society.
引用
收藏
页码:1415 / 1419
页数:5
相关论文
共 13 条
[1]
Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small cell lung cancer [J].
Borner, MM ;
Brousset, P ;
Pfanner-Meyer, B ;
Bacchi, M ;
Vonlanthen, S ;
Hotz, MA ;
Altermatt, HJ ;
Schlaifer, D ;
Reed, JC ;
Betticher, DC .
BRITISH JOURNAL OF CANCER, 1999, 79 (5-6) :952-958
[2]
Caputi M, 1999, ANTICANCER RES, V19, P825
[3]
Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair [J].
Cawkwell, L ;
Gray, S ;
Murgatroyd, H ;
Sutherland, F ;
Haine, L ;
Longfellow, M ;
O'Loughlin, S ;
Cross, D ;
Kronborg, O ;
Fenger, C ;
Mapstone, N ;
Dixon, M ;
Quirke, P .
GUT, 1999, 45 (03) :409-415
[4]
The BCL2 family: Regulators of the cellular life-or-death switch [J].
Cory, S ;
Adams, JM .
NATURE REVIEWS CANCER, 2002, 2 (09) :647-656
[5]
Cox Giles, 2000, Pathology and Oncolgy Research, V6, P87
[6]
Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers [J].
Groeger, AM ;
Esposito, V ;
De Luca, A ;
Cassandro, R ;
Tonini, G ;
Ambrogi, V ;
Baldi, F ;
Goldfarb, R ;
Mineo, TC ;
Baldi, A ;
Wolner, E .
HISTOPATHOLOGY, 2004, 44 (01) :54-63
[7]
Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer [J].
Han, H ;
Landreneau, RJ ;
Santucci, TS ;
Tung, MY ;
Macherey, RS ;
Shackney, SE ;
Sturgis, CD ;
Raab, SS ;
Silverman, JF .
HUMAN PATHOLOGY, 2002, 33 (01) :105-110
[8]
Immunohistochemical demonstration of apoptosis-regulated proteins, Bcl-2 and Bax, in resected non-small-cell lung cancers [J].
Hanaoka T. ;
Nakayama J. ;
Haniuda M. ;
Sato T.-A. .
International Journal of Clinical Oncology, 2002, 7 (3) :152-158
[9]
Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation [J].
Hu, YM ;
Benedict, MA ;
Wu, DY ;
Inohara, N ;
Núñez, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (08) :4386-4391
[10]
Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer [J].
Lai, RS ;
Wang, JS ;
Hsu, HK ;
Chang, HC ;
Lin, CH ;
Lin, MH .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2002, 32 (10) :393-397